Inclusion Criteria: • Adults, ages 18-65  History of CRSwNP including subjects with AERD Sinonasal culture demonstrating staph aureus at visit 1 History of FESS with patent sinus ostia sufficient to obtain culture and tissue samples from the middle meatus Asthma, if present, should be well controlled Atopic dermatitis, if present, should be well controlled Use of nasal saline irrigation and stable dosing (>1 month) of topical corticosteroids is permitted Intent of the physicians caring to start dupilumab therapy as part of subject's standard of care Subject meets FDA approved criteria for the use of dupilumab for nasal polyps  Exclusion Criteria:  Concurrent serious medical problem Uncontrolled asthma (ACT <20 at screening visit) Recent (within 60 days) use of oral corticosteroids Recent (within 60 days) urgent care, ED visit, or hospitalization for asthma Current smoker or has smoked >10 pack-years Biologic therapy including asthma biologic therapy in last 3 months Recent (within 1 month) change in CRS medical treatment (topical steroids, surfactants, irrigation protocol, etc. including changes in delivery volume or delivery methodology) Recent (within 6 weeks) upper respiratory infection Antibiotics within 6 weeks Pregnant or breast-feeding women Any contraindication to the use of dupilumab including hypersensitivity on previous administration